A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Program

Program
WEDNESDAY, MARCH 12
 
Session 1: Inflammation and metabolic stress (8:00 am to 9:50 am)
Moderator Introduction
David Harlan, M.D. (University of Massachusetts, Worcester, MA)

Immunomodulatory mechanisms in metabolic homeostatis and diseases
Chih-Hao Lee, Ph.D. (Harvard, Boston, MA)
 
Role of HDC in limiting adipose tissue inflammation
Alan Chait, M.D. (University of Washington, Seattle, WA)
 
Originsof beta cell stress in type 1 diabetes
Raghu Mirmira, M.D., Ph.D. (Indiana University, Indianapolis, IN)
 
Plenary lecture (9:50 am)
Genetics of MODY
Graeme Bell, Ph.D. (University of Chicago, Chicago, IL)
 
Session 2: Diabetic complications (10:35 am to 12:35 pm)
Moderator Introduction
Rama Natarajan, Ph.D. (Beckman Research Institute of City of Hope, Duarte, CA)
 
Diabetic nephropathy in the Pima Indians
Robert G. Nelson, M.D., Ph.D. (NIDDK/NIH, Phoenix, Arizona)
 
Role of lipid metabolism in diabetic nephropathy. New therapeutic targets
Moshe Levi, M.D. (University of Colorado Denver, Aurora, CO)
 
Glucose and white blood cells, Unhappy together
Ira Goldberg, M.D. (Columbia University, New York, NY)
 
MicroRNAs in diabetes nephropathy
Rama Natarajan, Ph.D. (Beckman Research Institute of City of Hope, Duarte, CA)
 
Funding opportunities (2:00 pm)
Human proteomics in diabetes at the NIDDK: Highlights and funding opportunities
Salvatore Sechi, Ph.D. (NIDDK/NIH, Bethesda, MD)
 
Session 3: Cell therapy – Where it stands today? (2:15 pm to 3:50 pm)
Moderator Introduction
Olle Korsgren, M.D., Ph.D. (Uppsala University Hospital, Uppsala, Sweden)
 
Clinical Islet Transplant Consortium: Current status and future directions
Andrew M. Posselt, M.D., Ph.D. (University of California San Francisco, San Francisco, CA
 
T cell depleting protocols in islet transplantation: How different are they?
Peter Stock, M.D., Ph.D. (UCSF Medical School, San Francisco, CA)
 
Recurrence of autoimmunity after islet transplantation
Joana Abreu, Ph.D. (Leiden University Medical Center, Leiden, The Netherlands)
 
Plenary lecture (3:50 pm)
Inflammation and insulin resistance
Jerrold Olefsky, M.D. (University of California, San Diego, La Jolla, CA

THURSDAY, MARCH 13
 
Session 1: Pathophysiology of type 1 diabetes (8:00 am to 10:00 am)
Moderator Introduction
Bart Roep, M.D., Ph.D. (Leiden University Medical Center, Leiden, The Netherlands)
 
Insulitis in type 1 diabetes
Peter In’t Veld, Ph.D. (Brussels Free University-VUB, Brussels, Belgium)
 
Virus detection in human pancreatic biopsies at disease onset
Knut Dahl-Jorgensen, M.D., DMSc (Oslo University Hospital, Oslo, Norway)
 
Exocrine pancreatic disorders and their potential roles in diabetes mellitus
Baoan Ji, M.D., Ph.D. (Mayo Clinic, Rochester, MN)
 
New discoveries by nPOD studies in the development of type 1 diabetes
Mark Atkinson, Ph.D. (University of Florida, Gainesville, FL)
 
Plenary lecture (10:15 am)
New staging classification system of type 1 diabetes in the at-risk setting
Richard Insel, M.D. (Juvenile Diabetes Research Foundation, New York, NY)
 
Session 2: Immune therapy (11:00 am to 1:00 pm)
Moderator Introduction
Mathias von Herrath, M.D. (La Jolla Institute for Allergy and Immunology, La Jolla, CA)
 
Primary prevention therapy with high dose oral insulin
Ezio Bonifacio, Ph.D. (DFG-Center for Regenerative Therapies Dresden, Dresden, Germany)
 
Dietary intervention and immunology of type 1 diabetes
Karsten Buschard, M.D., DVSc (Copenhagen University, Copenhagen, Denmark)
 
Antigen-specific immunotherapy
Carla Greenbaum, M.D. (Benaroya Research Institute at Virginia Mason, Seattle, WA)
 
Tolerogenic dendritic cells as tissue specific immune intervention strategy in type 1 diabetes
Bart Roep, M.D., Ph.D. (Leiden University Medical Center, Leiden, The Netherlands)
 
Session 3: New insights into diabetes pathophysiology (2:30 pm to 4:30 pm)
Moderator Introduction
Andrew Stewart, M.D. (Mount Sinai School of Medicine, New York, NY)
 
Gene-by-diet interactions in obesity: A systems genetic approach
Aldon J. Lusis, Ph.D. (University of California, Los Angeles, Los Angeles, CA)
 
The peripheral endocannabinoid/CBI receptor system as a therapeutic target for T2DM
George Kunos, M.D., Ph.D. (NIAAA/National Institutes of Health, Bethesda, MD)
 
Exercise, type 2 diabetes and epigenetics
Charlotte Ling, Ph.D. (Lund University, Malmo, Sweden)
 
The emerging role of the kidney in the regulation of glucose homeostasis and treatment of T2DM
Muhammad Abdul-Ghani, M.D. (University Texas Health Science Center, San Antonio, TX)
 
Poster Session (4:30 pm)

FRIDAY, MARCH 14
 
Session 1: Updates on diabetes technologies (8:00 am to 10:00 am)
Moderator Introduction
Aaron Kowalski, Ph.D. (Juvenile Diabetes, Research Foundation, New York, NY)
 
Ultra rapid insulins in closed loop AP systems
Howard Zisser, M.D. (Sansum Diabetes Research Institute, Santa Barbara, CA)
 
Nanomedicine for diabetes monitoring and treatment
John Pickup, M.D., Ph.D. (King’s College London, London, United Kingdom)
 
Sensor-augmented insulin pump therapy
Ohad Cohen, M.D. (Chaim Sheba Medical Center, Tel Hashomer, Israel)
 
A bionic pancreas in the wild: Outpatient studies of automated glycemia management
Steven Russell, M.D., Ph.D. (Massachusetts General Hospital Diabetes Research Center,Boston, MA)
 
Plenary lecture (10:15 am)
RNAi-based therapeutic strategies for metabolic disease
Michael P. Czech, Ph.D. (University of Massachusetts Medical School, Worcester, MA)
 
Debate: Controversies on GLP-1 agonists and DPP-4 inhibitors (11:00 am to 12:00 pm)
Moderator Introduction
Robert Vigersky, M.D. (Walter Reed National Military Medical Center, Washington, DC)
 
Controversies on GLP-1R agonists and DPP-4 inhibitors: Insights from and limitation of the science
Dan Drucker, M.D. (Mount Sinai Hospital, Toronto, Ontario, Canada)
 
On the safety of incretin-based anti-diabetic therapy: The NIDDK perspective
Dana Andersen, M.D. (NIDDK-NIH, Bethesda, MD)
 
Session 2: The new face of human beta cell biology (1:30 pm to 3:30 pm)
Moderator Introduction
Andrew Stewart, M.D. (Mount Sinai School of Medicine, New York, NY)
 
The human beta cell transcriptome
David Harlan, M.D. (University of Massachusetts, Worcester, MA)
 
Live-cell FACS approaches to human beta cell profiling
Markus Grompe, M.D. (Oregon Health & Science University, Portland, OR)
 
Modeling of human beta cell diseases in iPS cells
Rudy Leibel, M.D. (Columbia University, New York, NY)
 
Human pancreatic beta cell development: Plasticity and maturation from late gestation to childhood
Alvin Powers, M.D. (Vanderbilt University Medical Center, Nashville, TN)
 
Session 3: Current controversies in beta cell physiology (3:45 pm to 5:45 pm)
Moderator Introduction
David Harlan, M.D. (University of Massachusetts, Worcester, MA)
 
Elevated glucose and fatty acids restrict beta cell proliferation
Laura Alonso, M.D. (University of Massachusetts School of Medicine, Worcester, MA)
 
Elevated glucose and fatty acids promote beta cell proliferation
Vincent Poitout, DVM, Ph.D. (University of Montreal, Montreal, QC, Canada)
 
The IRS-signaling pathway is critical for beta-cell function, but is it insulin that activates it?
Christopher Rhodes, Ph.D. (University of Chicago, Chicago, IL)
 
Significance of insulin/IGF-1 receptors and their signaling proteins in pancreatic beta-cells
Rohit Kulkarni, M.D., Ph.D. (Joslin Diabetes Center, Boston, MA)
 
Presentation of Rachmiel Levine Scientific Achievement Awards and Dinner Lecture (6:30 pm)
Principal: Center for Physician Leadership
Fredric Tobis, M.D. (Center for Physician Leadership Training, Mercer Island, WA)

SATURDAY, MARCH 15
 
Session 1: New approaches to the treatment of type 1 diabetes (8:00 am to 10:00 am)
Moderator Introduction
Fouad Kandeel, M.D., Ph.D. (City of Hope, Duarte, CA)
 
Genetic testing in neonatal diabetes: An expanding list of possibilities
Siri Greeley, M.D., Ph.D. (The University of Chicago, Chicago, IL)
 
An update on START: A phase 2 study of anti-thymocyte globulin in new onset type 1 diabetes
Steve Gitelman, M.D. (University of California, San Francisco, San Francisco, CA)
 
Islet xenotransplantation: Where does it stand?
Henk-Jan Schuurman, Ph.D. (SchuBiomed Consultancy BV, Utrecht, The Netherlands)
 
Combinatorial development of materials for islet transplantation
Daniel Anderson, Ph.D. (Massachusetts Institute of Technology, Cambridge, MA)
 
Plenary lecture (10:15 am)
Translating mechanistic observations into effective clinical outcomes
Mario Ehlers, M.D., Ph.D. (Immune Tolerance Network, San Francisco, CA)
 
Session 2: Updates on clinical trials (11:00 am to 12:00 pm)
Moderator Introduction
Steve Gitelman, M.D. (University of California, San Francisco, San Francisco, CA)
 
TEDDY Study – Interim results
Marian Rewers, M.D., Ph.D. (University of Colorado, Aurora, CO)
 
Lesson learned from the Look AHEAD Trial
Anne Peters, M.D. (University of Southern California, Los Angeles, CA)
 
Session 3: Special issues in diabetes care (12:30 pm to 2:05 pm)
Moderator Introduction
Robert Vigersky, M.D. (Walter Reed National Military Medical Center, Washington, DC)

Perspectives on the mechanisms of bariatric surgery
Rohit Kohli, MBBS (Cincinnati Children’s, Cincinnati, OH)
 
Do genetic and molecular biomarkers help prevention of diabetes or not?
Geoffrey Walford, M.D. (Massachusetts General Hospital, Boston, MA)
 
Peri-operative management of diabetes
Robert Vigersky, M.D. (Walter Reed National Military Medical Center, Washington, DC)
 

March 13, 2013 Schedule

Session 1: Diabetic complications (8:00 am to 10:00 am)
Moderator
Rama Natarajan, Ph.D.( City of Hope , Duarte, CA)

Advanced glycation: AGE – RAGE and diabetic vascular complications
Ann Marie Schmidt, M.D.(Columbia University College of Physicians & Surgeons, New York, NY)

Stem cell approaches for vascular repair in diabetic retinopathy
Maria B. Grant, M.D.(University of Florida, Gainesville, FL)

Systems biology of diabetic kidney disease: Lessons learnt from animal and human models
Matthias Kretzler, M.D.(University of Michigan, Ann Arbor, MI)

Advances in drugs and drug targets for diabetic vascular complications, to ACE or ARB?
Mark Cooper, MBBS, Ph.D., FRACP(Baker ID Heart and Diabetes Institute, Melbourne Australia)

Plenary Lecture (10:15 am to 10:45 am)
Developing a combination cell therapy and delivery device for insulin-dependent diabetes
Eugene Brandon,Ph.D.(Viacyte, San Diego, CA)

Session 2:Clinical trials for type 1 diabetes(11:00 am to 1:00 pm)
Moderator
Matthias von Herrath, M.D. (La Jolla Institute for Allergy and Immunology, La Jolla, CA)

Optimal trial design in T1D
Richard Insel, M.D. (JDRF, New York, NY)

All recent-onset trials look the same, or do they?
David Harlan, M.D. (University of Massachusetts School of Medicine, Worcester, MA)

Anti-cytokine therapies overall
Mario Ehlers, M.D., Ph.D.(Immune Tolerance Network, San Francisco, CA)

High dose oral insulin in babies
Ezio Bonifacio, Ph.D.(DFG-Center for Regenerative Therapies Dresden, Dresden, Germany)

Session 3: Artificial pancreas (2:15 pm to 4:15 pm)
Moderator
Howard Zisser, M.D. (Sansum Diabetes Research Institute, Santa Barbara, CA)

System and control engineering for type 1 diabetes
Frank Doyle, Ph.D. (UCSB, Santa Barbara, CA)

The use of an automated glucose control system for overnight glucose control in adolescents with type 1 diabetes
Timothy Jones, M.D. (Princess Margaret Hospital, Perth, Australia)

Intensive insulin therapy using an artificial pancreas with closed-loop system
Kazuhiro Hanazaki, M.D., Ph.D.(Kochi Medical School, Kochi, Japan)

Implantable sensors - Animal data
Daniel Burnett, M.D. (TheraNova, LLC, San Francisco, CA)

Dinner and Presentation of Awards(5:30 pm to 7:00 pm)
Samuel Rahbar, M.D., Ph.D. Memorial Lecture
Fouad Kandeel, M.D., Ph.D. (City of Hope, Duarte, CA)

March 14, 2013 Schedule

Session 1: Epigenetics (8:00 am to 10:00 am)
Moderator
Rama Natarajan, Ph.D. (City of Hope, Duarte, CA)

Rodent models of epigenetic regulation of insulin resistance and diabetes
Rebecca Simmons, M.D.(Children's Hospital of Philadelphia, Philadelphia, PA)

 

Epigenomics of development and disease
Dustin Schones, Ph.D. (City of Hope, Duarte, CA)

 

Epigenetic regulation of alpha vs. beta cells
Anil Bhushan, Ph.D.(UCLA, Los Angeles, CA)

Beyondgenetics: The epigenetic code in chronic diabetic kidney disease
Dominic Raj, M.D. (George Washington University, Washington, DC)

Plenary Lecture (10:15 am to 10:45 am)
FoXO1, insulin action and metabolic effects
Domenico Accili, M.D.(Columbia University, New York, NY)

Session 2:Diabetes and the gut microbiome (11:00 am to 12:35 pm)
Moderator
Olle Korsgren, M.D., Ph.D. (Uppsala University Hospital, Uppsala, Sweden)

 

Bacteria reflux talk contributing to T1D
Olle Korsgren, M.D.,Ph.D.(Uppsala University Hospital, Uppsala, Sweden)

 

Fecal transplant talk – bridging T1D and T2D
Max Nieuwdorp, M.D., Ph.D.(Academic Medical Center-UvA, Amsterdam, The Netherlands)

 

Stopping autoimmune disease in type 1 diabetes: Exploiting the gut immune system
Chantal Mathieu, M.D., Ph.D. (Katholieke Universiteit, Leuven, Belgium)

Session 3: Islet imaging (2:00 pm to 4:00 pm)
Moderators
Al Powers, M.D.(Vanderbilt University, Nashville, TN)

 

The status of human beta cell specific monoclonal antibodies
Markus Grompe, M.D. (Oregon Health & Science University, Portland, OR)

Bioluminescent imaging of human pancreas islets
Jack Virostko, Ph.D.(Vanderbilt University, Nashville, TN)

 

Beta cell-specific imaging with zinc probes
A. Dean Sherry, Ph.D.(UT Southwestern, Dallas, TX)

 

VMAT2 ligand imaging of human beta cells in vivo
Gary Cline, Ph.D.(Yale University, New Haven, CT)

 

Poster Session (4:00 pm to 6:00 pm)

 

 

 

March 15, 2013 Schedule

Session 1: Glucose metabolism , beta cell biology and cancer (8:00 am to 10:00 am)
Moderator
David Harlan, M.D. (University of Massachusetts School of Medicine, Worcester, MA)

 

PTEN at the intersection of diabetes and cancer
Bangyan Stiles, Ph.D.(USC, Los Angeles, CA)

 

Glucose metabolism, ChREBP and proliferation in the beta cell
Donald Scott, Ph.D. (University of Pittsburgh, Pittsburgh, PA)

The putative association between glargine insulin and cancer
James Meigs, M.D. (Massachusetts General Hospital, Boston, MA)

 

RLIP76, a glutathione-conjugate transporter, plays a major role in cancer and the metabolic syndrome
Sanjay Awasthi, M.D. ( City of Hope , Duarte, CA)

Plenary lecture (10:15 am to 10:45 am)
Dysfunctional hematopoietic cells mediate chronic diabetic complications
Lawrence Chan, M.D. (Baylor College of Medicine, Houston, TX)

 

Session 2: Reversal of autoimmunity and transplantation tolerance (11:00 am to 1:00 pm)
Moderator
Bart Roep, M.D., Ph.D.(Leiden University Medical Center, Leiden, The Netherlands)

 

Reversal of autoimmunity via induction of mixed chimerism under a radiation-free anti-CD3/CD8 conditioning
Defu Zeng, Ph.D.(City of Hope, Duarte, CA)

 

Tolerance to organ transplants in humans
Samuel Strober, M.D.(Stanford University, Stanford, CA)

 

MSCs potential in clinical islet transplantation therapy
Yoko Mullen, M.D., Ph.D. (City of Hope, Duarte, CA)

MSC in T2D
Antonello Pileggi, M.D., Ph.D. (University of Miami, Miami, FL)

 

Debate: Is there evidence for distinct courses in loss of beta-cell function in T1D?(2:15 pm to 3:15 pm)
Moderator
Bart Roep, M.D., Ph.D.(Leiden University Medical Center, Leiden, The Netherlands)

Position 1
Carla Greenbaum, M.D. (Benaroya Research Institute at Virginia Mason, Seattle, WA)

Position 2
Kevan Herold, M.D. (Yale University, New Haven, CT)

 

Inflammation, macrophages and ER stress (3:30 pm to 5:30 pm)
Moderator
Janice Huss, Ph.D. (City of Hope, Duarte, CA)

Diabetes -accelerated atherosclerosis and inflammation - Revealing the picture one piece at a time
Karin Bornfeldt, Ph.D.(University of Washington, Seattle, WA)

 

Beta-cell suicide
Feroz Papa, M.D., Ph.D.(UCSF, San Francisco, CA)

 

Immunologic regulation of adipose tissue function
Anthony W. Ferrante, M.D., Ph.D. (Columbia University, New York, NY)

Regulatory myeloid cells mediated immune suppression vs. inflammation
Shu-Hsia Chen, Ph.D. (Mount Sinai School of Medicine, New York, NY)

 

March 16, 2013 Schedule

Session 1: Human pancreas development (8:00 am to 10:00 am)
Moderator
Andrew Stewart, M.D. (Mount Sinai School of Medicine, New York, NY)

 

A careful look at human endocrine pancreas development: Part 1
Marcela Brissova, Ph.D. (Vanderbilt University, Nashville, TN)

 

A careful look at human endocrine pancreas development: Part 2
Philip DiIorio, Ph.D. (University of Massachusetts School of Medicine, Worcester, MA)

 

Endocrine pancreas development in the non-human primate pancreas
Lynley Pound, Ph.D. (Oregon National Primate Research Center, Beaverton, OR)

Development of authentic human beta cell lines
Philippe Ravassard,Ph.D. (ICM-INSERM, Paris, France)

Debate: The beta-cell will be preserved with currently available therapy in type 2 diabetes(10:15 am to 11:15 am)
Moderator
Robert Vigersky, M.D. (Walter Reed National Military Medical Center, Washington, DC)

Position 1
Philip Raskin, M.D. (UT Southwestern Medical Center, Dallas, TX)

Position 2
John Leahy, M.D. (University of Vermont, Colchester, VT)

 

Session 2: Clinical controversies in diabetes care (11:30 am to 1:30 pm)
Moderator
Fouad Kandeel, M.D., Ph.D. (City of Hope, Duarte, CA)

 

Glycemic control diabetes complications: Implications for care in the post-ACCORD era
David Kendall, M.D. (Lilly Diabetes, Minneapolis, MN)

DCCT/EDIC Research Group update
John M. Lachin, Sc.D. (The George Washington University, Rockville, MD)

Use of bariatric surgery to cure diabetes
Philip Schauer, M.D. (Cleveland Clinic, Cleveland, OH)

Glycemic variability
Robert Vigersky, M.D.(Walter Reed National Military Medical Center, Washington, DC)

 

 
City of Hope combines compassionate care with the best and most innovative science. Our 100+ acre campus is designed to meet the full range of needs of our patients and families. This guide is designed to help you take advantage of all that is offered at City of Hope.
To make an appointment for yourself, a family member or a friend, please complete and submit our Become a Patient Request Form, or call City of Hope at
800-826-HOPE (4673).
Physician's Bulletin
City of Hope’s Physician’s Bulletin is a publication for healthcare professionals that provides news and information about current research activities and significant trends in cancer treatment options.
Contact Us
Phone: (800) 826-HOPE (4673)
 
Hours: M – F, 8 a.m. to 5 p.m. (PST)
 
Calls received after 5 p.m. will be returned the next business day.
 
 
Patient Care
Whether you're becoming a patient or referring one, learn all of the ways City of Hope can help you begin your patient or caregiver journey.